Primus Pharmaceuticals, Inc.: New Clinical Study Shows Limbrel(TM) as Effective as Naproxen for Knee Osteoarthritis

SCOTTSDALE, Ariz.--(BUSINESS WIRE)--Limbrel™ (a prescription medical food) taken at 500 mg twice a day was shown to be as effective as naproxen 500 mg taken twice a day for knee osteoarthritis, according to a clinical study presented at the 7th International Cartilage Repair Society (ICRS) World Congress recently held in Warsaw, Poland.1 “In this study, the Limbrel and naproxen groups performed nearly identically, showing significant overall improvements in conventional osteoarthritis efficacy measures, including physician and subject global assessments, and WOMAC, a key measure of mobility, stiffness and joint discomfort,” said the lead author Robert Levy, M.D., a rheumatologist for over 30 years and director of clinical development at Primus Pharmaceuticals. “This suggests that Limbrel can be an effective prescription product for the management of osteoarthritis.”
MORE ON THIS TOPIC